Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by Pandoraon Apr 05, 2022 3:39pm
199 Views
Post# 34577957

RE:RE:The 23 Optimized Patients

RE:RE:The 23 Optimized Patients
StevenBirch wrote: Thanks Eog, that looks good. It's too bad they can't split off the pending number.


Seeing as there are only 35 or 38 patients, then for the sake of the majority of the number of investor's who are "laymen", you would think that with today's technology in spreadsheets they could make up a list for news release purposes that gives a standing for each individual patient from beginning to current status in the appropriate time windows of 90, 180, 270, 360 and 450 days -- or is that too much to ask?

For the purpose of advising investors, as opposed to advising the "experts" in the medical field and the regulatory field, I think it would achieve a far better response.

I guess I can be listed as a dreamer!
<< Previous
Bullboard Posts
Next >>